financetom
Business
financetom
/
Business
/
CFM re-allocates some engines in boost to Airbus, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CFM re-allocates some engines in boost to Airbus, sources say
Nov 27, 2024 3:14 AM

MUNICH, Nov 27 (Reuters) - Jet engine maker CFM has

agreed to divert some engines to Airbus to narrow a

supply gap as the planemaker battles to hit end-year targets,

three people familiar with the matter said.

Under the agreement reached this month, CFM is expected to

divert to Airbus some engines that had initially been allocated

to the aftermarket, the sources said.

The number of engines involved was not immediately clear,

but has raised confidence that Airbus can take a step towards

meeting challenging delivery targets of "around 770" aircraft

for 2024, barring other supply setbacks, they added.

"We are working hard to meet demand from our customers and

to maximise fleet utilisation," said a spokesperson for CFM,

jointly owned by GE Aerospace and Safran.

"We are working with our suppliers including our engine

suppliers to deliver on the commitments," an Airbus spokesperson

said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apellis Pharmaceuticals Insider Sold Shares Worth $1,340,597, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $1,340,597, According to a Recent SEC Filing
Sep 20, 2024
05:26 PM EDT, 09/17/2024 (MT Newswires) -- A. Sinclair Dunlop, Director, on September 16, 2024, sold 37,000 shares in Apellis Pharmaceuticals ( APLS ) for $1,340,597. Following the Form 4 filing with the SEC, Dunlop has control over a total of 247,526 shares of the company, with 147,526 shares held directly and 100,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1492422/000095017024107411/xslF345X05/ownership.xml Price: 37.01,...
Hamilton Thorne's Shareholders Approve Takeover by Cradle Acquisition
Hamilton Thorne's Shareholders Approve Takeover by Cradle Acquisition
Sep 20, 2024
05:35 PM EDT, 09/17/2024 (MT Newswires) -- Hamilton Thorne ( HTLZF ) said late Tuesday its shareholders approved a plan for its acquisition by Cradle Acquisition, which is taking the company private. The approval came during a special meeting held today, the company added. Cradle Acquisition is also set to acquire Cook Medical's ART product portfolio and merge it with...
Atlassian Insider Sold Shares Worth $1,311,691, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,311,691, According to a Recent SEC Filing
Sep 20, 2024
05:25 PM EDT, 09/17/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on September 16, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,311,691. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 79,480 shares of the company, with 79,480 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024006849/xslF345X05/primarydocument.xml Price: 156.00, Change: +0.18, Percent...
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
Sep 20, 2024
Sept 17 (Reuters) - The independent directors of genetic testing firm 23andMe said on Tuesday they have resigned from the company's board after not receiving a satisfactory take-private offer from CEO Anne Wojcicki. Wojcicki, who has been trying to take the company private since April, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates...
Copyright 2023-2026 - www.financetom.com All Rights Reserved